Cart
sales@molnova.com
Ethyl6-bromo-1H-indole-3-carboxylate
CAS No. 103858-55-5
Ethyl6-bromo-1H-indole-3-carboxylate( Ethyl 6-Bromoindole-3-carboxylate | ZINC13379655 | ethyl 6-bromo-3-indolecarboxylate )
Catalog No. M29568 CAS No. 103858-55-5
Ethyl6-bromo-1H-indole-3-carboxylate is a marine derived natural products found in Pleroma menoui.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 45 | Get Quote |
|
| 10MG | 68 | Get Quote |
|
| 25MG | 115 | Get Quote |
|
| 50MG | 173 | Get Quote |
|
| 100MG | 258 | Get Quote |
|
| 200MG | 388 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEthyl6-bromo-1H-indole-3-carboxylate
-
NoteResearch use only, not for human use.
-
Brief DescriptionEthyl6-bromo-1H-indole-3-carboxylate is a marine derived natural products found in Pleroma menoui.
-
DescriptionEthyl6-bromo-1H-indole-3-carboxylate is a marine derived natural products found in Pleroma menoui.
-
In Vitro——
-
In Vivo——
-
SynonymsEthyl 6-Bromoindole-3-carboxylate | ZINC13379655 | ethyl 6-bromo-3-indolecarboxylate
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number103858-55-5
-
Formula Weight268.11
-
Molecular FormulaC11H10BrNO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(OCC)C1=CNC=2C=C(Br)C=CC21
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
RS 09
TLR4 agonist. Promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro. Acts as an adjuvant in vivo; enhances X-15 specific antibody serum concentrations, when administered with X-15-KLH in mice.
-
Chonglou Saponin II
Chonglou Saponin II has hemostasis, expectorant, bacteriostasis, anticytotoxic, anti-pregnancy kill sperm effects.
-
Disitamab vedotin
Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker.
